Creating new insecticides to fight malaria by targeting mosquito brain receptors
Developing resistance-breaking insecticides at mosquito muscarinic acetylcholine receptors to reduce malaria transmission
This study is working on new insecticides that can specifically target the nervous system of malaria-carrying mosquitoes, helping to control their populations better, especially those that have become resistant to current treatments.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Polytechnic Inst and St Univ NIH-funded |
| Lab location | 1 site (Blacksburg, United States) |
| Project ID | NIH-10471845 on NIH RePORTER |
What this research studies
This research focuses on developing new insecticides that specifically target the muscarinic acetylcholine receptors in mosquitoes, which are crucial for their nervous system function. By understanding the unique pharmacology of these receptors in the malaria-carrying mosquito species, Anopheles gambiae, the researchers aim to create insecticides that are effective against resistant mosquito populations. The approach involves using chemical probes and nutrient conjugates to enhance the delivery of these insecticides, potentially leading to more effective mosquito control strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living in malaria-endemic regions who are at risk of malaria infection.
Not a fit: Patients who do not reside in malaria-endemic areas or those who are not at risk of malaria will likely not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce malaria transmission by improving mosquito control methods.
How similar studies have performed: Other research has shown promise in targeting insect receptors for pest control, indicating that this approach could be effective.
Where this research is happening
Blacksburg, United States
- Virginia Polytechnic Inst and St Univ — Blacksburg, United States (Active)
Researchers
- Principal investigator: Gross, Aaron Donald — Virginia Polytechnic Inst and St Univ
- Study coordinator: Gross, Aaron Donald
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.